surmount-1 tirzepatide weight loss percent nejm 2022 SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions GLP-1 Medications for Weight Loss:

However, if you are using a lower dose from a multi-dose vial, the vial may last longer in terms of number of doses, potentially exceeding the beyond-use date before you finish it

Shift workers Rotating shift work creates unique challenges for weekly injection timing

One trial showed participants taking 7.2mg weekly losing on average 18.7%, with many reaching 20-25% weight loss thresholds

Tirzepatide is the first in its class, being a single-molecule agonist of both the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide (GIP), hence the term dual agonist or twincretin

Semaglutide is a selective GLP-1 agonist only

Most GLP-1 telehealth platforms are designed to process volume a quick intake form, an approval, a prescription, and then youre largely on your own